Trial Profile
DelIVery for Pulmonary Arterial Hypertension (PAH) Clinical Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Acronyms PAH-D
- Sponsors Medtronic
- 14 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Dec 2032.
- 14 May 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.
- 10 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Nov 2021.